PSTI - Pluristem Therapeutics Inc.
| Previous Close | 3.8000 |
| Open | 3.8500 |
| Bid | 3.7800 x 1100 |
| Ask | 3.8700 x 1400 |
| Day's Range | 3.7500 - 3.9000 |
| 52 Week Range | 3.1100 - 11.9000 |
| Volume | 45,653 |
| Avg. Volume | 51,781 |
| Market Cap | 57.017M |
| Beta (3Y Monthly) | 1.02 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.5230 |
| Earnings Date | Feb 15, 2019 - Feb 18, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 16.17 |
- GlobeNewswire
Pluristem Reaches Milestone in its Phase III Muscle Injury Study, Completes 50% Enrollment
Pluristem Therapeutics Inc. (PSTI) (PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that it has completed enrollment of 50% of the 240 patients planned for its ongoing Phase III PLX-PAD study of muscle regeneration. There are currently no approved treatments for the post-operative regeneration of injured or weak skeletal muscle, and up to 30% of hip fracture patients die within one year of surgery due to long-term complications resulting from immobility, with high financial costs of hospitalization and rehabilitation.
- Insider Monkey
Hedge Funds Have Never Been More Bullish On Pluristem Therapeutics Inc. (PSTI)
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the third quarter. You can find articles about an individual hedge fund's trades on numerous financial […]
- Simply Wall St.
Pluristem Therapeutics (NASDAQ:PSTI) Will Have To Spend Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
- GlobeNewswire
Pluristem Therapeutics CEO Issues Shareholder Update
Pluristem Therapeutics Inc. (PSTI) (PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today issued an update to its shareholders from its Chief Executive Officer, Yaky Yanay. PLX-R18, for the treatment of acute radiation syndrome (ARS), is advancing towards an important study with the potential for demonstrating the superiority of our cell therapy product versus the current standard of treatment, as we target governmental purchase contracts.
- GlobeNewswire
RESTORE Consortium to Host the 1st Advanced Therapies Science Meeting, Aiming to Translate Promising Research into a Game Changer in Healthcare
RESTORE Consortium, of which Pluristem is a leading member, is competing for up to a €1 billion award by the European CommissionWinner announcement is expected in May 2020.
- Zacks
Pluristem Therapeutics Sees Hammer Chart Pattern: Time to Buy?
Pluristem Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.
- Simply Wall St.
Pluristem Therapeutics Inc. (NASDAQ:PSTI) Insiders Increased Their Holdings
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
- GlobeNewswire
Pluristem Therapeutics Recaps Key Opinion Leader Call Reviewing Hematological Programs
PLX cell therapy was granted an Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of ARS and incomplete hematopoietic recovery following hematopoietic cell transplantation (HCT). An overview of HCT was provided by Dr. Jacob M. Rowe, MD, Chief of the Department of Hematology and The Ann and Pinky Sohn Chair in Hemato-Oncology at the Shaare Zedek Medical Center in Jerusalem and Emeritus Professor at the Technion, Israel Institute of Technology in Haifa, a member in the company’s ongoing hematology program steering committee.
- GlobeNewswire
Pluristem Therapeutics to Host Key Opinion Leader Call on Its Acute Radiation Syndrome and Hematological Programs
Pluristem Therapeutics (PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced additional information relating to its live Key Opinion Leader (KOL) call regarding its hematological programs on September 16, 2019. The call will feature presentations by Jacob M. Rowe, MD and Bert. W. Maidment, Ph.D, and will include discussions regarding the findings from Pluristem’s ongoing clinical study in hematological deficiencies, as well as opportunities and future product development.
- Simply Wall St.
Did Changing Sentiment Drive Pluristem Therapeutics's (NASDAQ:PSTI) Share Price Down A Painful 86%?
Long term investing works well, but it doesn't always work for each individual stock. We don't wish catastrophic...
- GlobeNewswire
Pluristem Therapeutics to Host Key Opinion Leader Call on its Acute Radiation Syndrome and Hematological Deficiencies Programs
Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that the company will host a live Key Opinion Leader (KOL) call on its hematological programs on September 16, 2019. The call will feature presentations by KOLs and Pluristem’s management who will explain and discuss the status of the company’s radiation programs with the U.S government, including an overview of recent Department of Defense (DoD) radiation data, potential markets and expected milestones. In addition, KOLs will discuss findings from Pluristem’s ongoing clinical study in hematological deficiencies, as well as opportunities and future product development.
- Reuters
OFFICIAL CORRECTION-Pluristem gets positive results from radiation treatment trials
Israel's Pluristem Therapeutics Inc reported on Wednesday positive results from a series of studies in animals of its placenta-based stem cell therapy to treat acute radiation syndrome (ARS). The studies were conducted by the U.S. Department of Defense’s Armed Forces Radiobiology Research Institute. The tests, conducted via the Food and Drug Administration's "animal rule pathway" as ARS cannot be tested in humans, were designed to evaluate Pluristem's PLX-R18 as a preventative treatment for ARS before radiation exposure.
- GlobeNewswire
Pluristem and U.S. Department of Defense Present Positive Data from Studies Testing PLX-R18 as a Prophylactic Treatment for Acute Radiation Syndrome
PLX-R18 demonstrated significant increase in survival rates and recovery of the three blood lineagesData is jointly presented at the 2019 Radiation Injury Treatment Network.
- Benzinga
The Daily Biotech Pulse: Setback For Bristol-Myers Squibb, Gemphire Explodes, Lilly's Nasal Low Blood Sugar Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 24) Acasti Pharma Inc (NASDAQ: ACST ) Cardiovascular Systems ...
- GlobeNewswire
Pluristem Therapeutics’ CEO Issues Shareholders Update
Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today issued an update to its shareholders from its Chief Executive Officer, Yaky Yanay, commenting on the Company’s proposed reverse stock split. Today we announced a 1-for-10 reverse split of the company’s authorized, as well as issued and outstanding shares of common stock and authorized preferred stock.
- Benzinga
The Daily Biotech Pulse: Jounce Jumps On Licensing Deal, Regulus Hit With Partial Clinical Hold, Genomic Health Added to S&P SmallCap Index
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 23) Akero Therapeutics Inc (NASDAQ: AKRO ) Mirum Pharmaceuticals ...
- GlobeNewswire
Pluristem Announces One-for-Ten Reverse Split of its Common Shares
The reverse split will be effective as of market open on July 25, 2019 on Nasdaq. Pursuant to Part 3 of the Tel-Aviv Stock Exchange Regulations (Chapter A, Section B(1)), the Company’s common stock will not trade on the Tel-Aviv Stock Exchange on July 25, 2019.
- Simply Wall St.
What Kind Of Investor Owns Most Of Pluristem Therapeutics Inc. (NASDAQ:PSTI)?
A look at the shareholders of Pluristem Therapeutics Inc. (NASDAQ:PSTI) can tell us which group is most powerful...
- GlobeNewswire
Pluristem and U.S. Department of Defense to Announce Data from Studies Testing PLX-R18 as a Prophylactic Treatment for Acute Radiation Syndrome at RITN
The animal studies, conducted following guidance from the U.S. Food and Drug Administration (FDA) relating to its animal rule pathway, are designed to evaluate PLX-R18 as a potential prophylactic countermeasure against acute radiation syndrome (ARS) administered prior to radiation exposure. In addition to the DoD study, PLX-R18 is also being evaluated by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), as a treatment following radiation exposure.
- GlobeNewswire
Pluristem Therapeutics’ CEO Issues Shareholder Letter
Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today issued an update to its shareholders from its Chief Executive Officer, Yaky Yanay.
- GlobeNewswire
Pluristem Completes Transition Period of Co-CEO Structure Yaky Yanay appointed as Chief Executive Officer and Zami Aberman appointed as Executive Chairman of the Board
“I am proud and pleased in successfully completing the transition period and the appointment of Yaky as Pluristem’s sole CEO,” said Zami Aberman. “As Executive Chairman I will continue to take an active role in shaping Pluristem’s corporate development and business strategy as we are advancing towards completion of our phase III studies and targeting our marketing phase.
- GlobeNewswire
Pluristem Strengthens Its Manufacturing Competitive Advantage, Presents its First Proprietary Serum-Free Cell Therapy Product
This serum-free media formulation was developed using Pluristem’s deep understanding in cell therapy industrial scale production standards, and the quality methods designed to support implementation in Phase III development and marketing. Achieving this significant technological challenge enables Pluristem large-scale, highly consistent production with operational independency from third-party suppliers for standard serum, an expensive and quantity limited product. PLX-R18 is the first product that Pluristem intends to manufacture using the serum-free media.
- Simply Wall St.
Pluristem Therapeutics Inc. (NASDAQ:PSTI): Are Analysts Optimistic?
Pluristem Therapeutics Inc.'s (NASDAQ:PSTI): Pluristem Therapeutics Inc., together with its subsidiary, Pluristem...
- GlobeNewswire
Lead Physicians in Pluristem’s Pivotal Study in Critical Limb Ischemia Publish Peer-Reviewed Paper
The pivotal study is also designed to measure long-term outcomes and collect parameters to assess the potential economic benefit of this kind of treatment. Additionally, an invited commentary that also appears in EJVES lends strong support for the study’s design and potential impact.
- GlobeNewswire
Pluristem Files Patent Application for the Use of its Advanced Manufacturing Technology in the Cannabis Industry
Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that it has filed a U.S. provisional patent application titled “Methods and Compositions for Producing Cannabinoids,” which covers the use of Pluristem’s state-of-the-art, proprietary 3-D cell culturing technology for the potential manufacturing of cannabinoid-producing cells.
